-transparent.png){kind=logo}
Out of 64 patients with rheumatoid arthritis (RA), 42 were treated with D-penicillamine (D-Pa) for more than 6 months and 22 for less than 6 months. The latter patients were excluded from the evaluation of the effect. The former patients were treated with doses of 600-1 250 mg daily for 6-41 months (mean 16.8). The clinical effect was retrospectively assessed as favourable in 24 patients, 12 did not respond and the effect could not be assessed in 6. The clinical assessment was supported by significant reductions of ESR and orosomucoid. Adverse reactions, although rarely serious, led to withdrawal of the drug in 25 (39%) of the 64 patients. It is concluded that D-Pa is a valuable drug in the treatment of severe RA.
O Börjesson, and
L P Knutsson, and
B Svensson
January 1977,
The British journal of clinical practice,
O Börjesson, and
L P Knutsson, and
B Svensson
June 1985,
The Journal of rheumatology,
O Börjesson, and
L P Knutsson, and
B Svensson
September 1974,
JAMA,
O Börjesson, and
L P Knutsson, and
B Svensson
May 1977,
Seminars in arthritis and rheumatism,
O Börjesson, and
L P Knutsson, and
B Svensson
January 1981,
The Journal of rheumatology. Supplement,
O Börjesson, and
L P Knutsson, and
B Svensson
January 1975,
Reumatologia,
O Börjesson, and
L P Knutsson, and
B Svensson
September 1973,
British medical journal,
O Börjesson, and
L P Knutsson, and
B Svensson
September 1972,
Annals of the rheumatic diseases,
O Börjesson, and
L P Knutsson, and
B Svensson
February 1977,
Proceedings of the Royal Society of Medicine,
O Börjesson, and
L P Knutsson, and
B Svensson
April 1983,
Revue du rhumatisme et des maladies osteo-articulaires,
